Description
BSE announces new ISIN number for Welcure Drugs & Pharmaceuticals Ltd following sub-division of equity shares from Rs.10/- to Re.1/-.
Summary
BSE has announced the new ISIN number for Welcure Drugs & Pharmaceuticals Ltd (Scrip Code: 524661) following the sub-division of equity shares from face value of Rs.10/- to Re.1/-. The new ISIN INE331C01025 will be effective for trades from the ex-date of October 16, 2025.
Key Points
- New ISIN number assigned: INE331C01025
- Company: Welcure Drugs & Pharmaceuticals Ltd (Scrip Code: 524661)
- Corporate action: Sub-division of equity shares from Rs.10/- to Re.1/- (1:10 split)
- Ex-date for new ISIN: October 16, 2025
- Reference: DR-737/2025-2026
- Continuation of Exchange Notice No. 20251013-18 dated October 13, 2025
Regulatory Changes
No regulatory framework changes. This is a standard corporate action notice informing about ISIN change following share sub-division.
Compliance Requirements
- Trading members must use the new ISIN number INE331C01025 for all trades in Welcure Drugs & Pharmaceuticals Ltd from October 16, 2025 onwards
- All trading systems must be updated to reflect the new ISIN and face value change
- The new ISIN applies to equity shares of Re.1/- each (post sub-division)
Important Dates
- Notice Date: October 14, 2025
- Ex-Date: October 16, 2025 (new ISIN becomes effective)
- Previous Notice Reference: October 13, 2025 (Exchange Notice No. 20251013-18)
Impact Assessment
Market Impact: Medium - The share sub-division from Rs.10 to Re.1 (1:10 split) will increase the number of outstanding shares by 10 times while reducing the trading price proportionally. This typically improves liquidity and makes shares more accessible to retail investors.
Operational Impact: Trading members and market participants must ensure their systems are updated with the new ISIN number before the ex-date to avoid trade execution issues. Existing shareholders will receive 10 shares for every 1 share held, improving marketability of the stock.
Impact Justification
Stock split affects existing shareholders and trading systems but is a routine corporate action with clear implementation date